[Thrombocytopenia in HCV infection. Natural interferon as an alternative therapy].
The current standard of care for the treatment of hepatitis C virus (HCV) infection is the combination of pegylated interferon and ribavirin. The interferon-based therapy is contraindicated in patients with HCV-associated thrombocytopenia. The pathogenesis of HCV-associated thrombocytopenia is still unclear. In this paper the main aspects of HCV-associated thrombocytopenia and alternative therapy with natural interferon (Alfaferone) are presented.
Krzowska-Firych
Joanna
J
Katedra i Klinika Chorób Zakaźnych Akademii Medycznej im. prof. F. Skubiszewskiego w Lublinie. firychjdr@poczta.onet.pl
Modrzewska
Roma
R
Kiciak
Sławomir Grzegorz
SG
D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000821:virology*
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin